News

OCRFA Awarded 4-Star Rating from Charity Navigator

OCRFA Awarded 4-Star Rating from Charity Navigator

June 6, 2018

(June 6, 2018) OCRFA is pleased to announce we have once again earned a 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, and to organizational transparency and accountability, as we continue to strive toward a cure for … Continued

OCRA News

“Ask the Experts” at OCRFA’s Ovarian Canc...

“Ask the Experts” at OCRFA’s Ovarian Cancer National Conference

May 25, 2018

Don’t miss your chance to hear top experts speak at the “Ask the Experts” session at OCRFA’s Ovarian Cancer National Conference. Ask the Experts panelists include: We’ve extended our Ask the Experts Q&A session, giving you more time to learn and more time to answer your questions about ovarian cancer research, science and clinical trials. … Continued

Events

The 2018 American Association for Cancer Research Annual Me...

The 2018 American Association for Cancer Research Annual Meeting

May 18, 2018

(May 18, 2018) Just last month, three of OCRFA’s research advocates attended the 5 day AACR meeting in Chicago, Illinois to learn about new therapies and innovative technology, stay up to date on current projects, and attend lectures from ovarian cancer researchers such as Dr. Anil Sood of MD Anderson and Dr. Dineo Khabele of … Continued

Research

Rebecca’s Journey

Rebecca’s Journey

May 15, 2018

Donate Now It was August of 2001 when I awoke one evening with a stabbing pain in my side that was so serious, I headed straight to the emergency room. I left with a diagnosis of “depression” and a bottle of painkillers. Something inside me – a gut feeling I can’t explain – told me … Continued

Community

Hormone Replacement Therapy After Oophorectomy Is Not Shown...

Hormone Replacement Therapy After Oophorectomy Is Not Shown to Increase Risk of Breast Cancer in BRCA1 Mutation Carriers

May 4, 2018

(May 4, 2018) JAMA Oncology recently published a study that looked at the risk of breast cancer in BRCA1 carriers who underwent a prophylactic bilateral salpingo-oophorectomy, a surgery that removes both ovaries before any sign of disease, followed by hormone replacement therapy (HRT). Eight hundred and seventy two women were followed for around 7.5 years … Continued

Research

OCRFA Funded Study Focuses on the Dissemination of Ovarian ...

OCRFA Funded Study Focuses on the Dissemination of Ovarian Cancer

April 27, 2018

(April 27, 2018) An OCRFA supported study, recently published in Oncogene, delved into the mechanics of how ovarian cancer spreads throughout the body. Researchers at Johns Hopkins, including OCRFA grantee and lead author Ie-Ming Shih, MD, PhD, investigated spleen tyrosine kinase (SYK), which is heavily involved in ovarian cancer tumor progression, in an effort to … Continued

OCRA News

Study Shows Survival Advantage of Primary Cytoreductive Sur...

Study Shows Survival Advantage of Primary Cytoreductive Surgery

April 26, 2018

(April 26, 2018) The International Journal of Gynecological Cancer recently featured a retrospective study on the treatment patterns of women with advanced high-grade serous ovarian carcinoma (HGSC). Of the 852 women with HGSC included in the study, 53% of them underwent primary cytoreductive surgery (PCS), or surgery before chemotherapy to remove as much of the tumor … Continued

Research

OCRFA Funded Study Explores Implant that Detects Ovarian Ca...

OCRFA Funded Study Explores Implant that Detects Ovarian Cancer Biomarker

April 24, 2018

(April 24, 2018) Science Advances recently published a study that succeeded in detecting HE4, a biomarker for high-grade serous ovarian cancer (HGSC), by implanting an optical sensor near a disease site in mice. HE4, like CA-125, is approved by the U.S. Food and Drug Administration as a biomarker for HGSC. However, these biomarkers are more … Continued

OCRA News

Register for OCRFA’s Ovarian Cancer National Conferen...

Register for OCRFA’s Ovarian Cancer National Conference on July 13-15 in Washington, DC

April 19, 2018

Join ovarian cancer survivors, caregivers, researchers and healthcare providers at OCRFA’s Ovarian Cancer National Conference – an informative and transformative weekend of hope, inspiration and fun. Get a front row seat at expert plenary and breakout sessions, from the newly-expanded Ask the Experts, to sessions on understanding PARP inhibitors, and sexual health after cancer. Learn … Continued

Events

Vaccine for Ovarian Cancer Shows Promising Results in Pilot...

Vaccine for Ovarian Cancer Shows Promising Results in Pilot Trial

April 17, 2018

(April 17, 2018) Science Translational Medicine recently published a University of Pennsylvania Perelman School of Medicine/University of Lausanne, Switzerland study on using a patient’s immune system to fight their cancer. In this pilot trial, 25 patients with advanced epithelial recurrent ovarian cancer were either given the vaccine alone, with the chemotherapy drug bevacizumab, or a … Continued

Research

Join us for an intimate evening of tastings at Turn Up the ...

Join us for an intimate evening of tastings at Turn Up the Heat Boston

April 12, 2018

A tantalizing menu of irresistible treats, crafted by the region’s top female chefs, mixologists and restaurateurs, awaits you at Boston College Club on May 8th. Indulge to your heart’s delight, and be sure to save room for rich chocolate buttermilk cake with dark chocolate ganache, courtesy of Pastry Chef Mareena McKenzie of Strip-T’s. Mareena was … Continued

Events

FDA Approves Rucaparib as Maintenance Treatment for Platinu...

FDA Approves Rucaparib as Maintenance Treatment for Platinum Sensitive Recurrent Ovarian Cancer

April 10, 2018

(April 10, 2018) Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had at least a partial response to platinum based chemotherapy have a new, FDA approved option for maintenance therapy. The evidence that led to the FDA approving rucaparib comes from the phase 3 ARIEL3 clinical trial, which enrolled 564 … Continued

Research